164 related articles for article (PubMed ID: 31578574)
1. Downregulation of MUTYH contributes to cisplatin‑resistance of esophageal squamous cell carcinoma cells by promoting Twist‑mediated EMT.
Guo Y; Jia Y; Wang S; Liu N; Gao D; Zhang L; Lin Z; Wang S; Kong F; Peng C; Liu Y
Oncol Rep; 2019 Dec; 42(6):2716-2727. PubMed ID: 31578574
[TBL] [Abstract][Full Text] [Related]
2. Tex10 promotes stemness and EMT phenotypes in esophageal squamous cell carcinoma via the Wnt/β‑catenin pathway.
Xiang X; Xiong R; Yu C; Deng L; Bie J; Xiao D; Chen Z; Zhou Y; Li X; Liu K; Feng G
Oncol Rep; 2019 Dec; 42(6):2600-2610. PubMed ID: 31638260
[TBL] [Abstract][Full Text] [Related]
3. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
4. Establishment and biological analysis of the EC109/CDDP multidrug-resistant esophageal squamous cell carcinoma cell line.
Wen J; Zheng B; Hu Y; Zhang X; Yang H; Luo KJ; Zhang X; Li YF; Fu JH
Oncol Rep; 2009 Jul; 22(1):65-71. PubMed ID: 19513506
[TBL] [Abstract][Full Text] [Related]
5. HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2.
Li J; Sang M; Zheng Y; Meng L; Gu L; Li Z; Liu F; Wu Y; Li W; Shan B
Exp Cell Res; 2021 Dec; 409(1):112891. PubMed ID: 34688610
[TBL] [Abstract][Full Text] [Related]
6. RIT1 suppresses esophageal squamous cell carcinoma growth and metastasis and predicts good prognosis.
Feng YF; Lei YY; Lu JB; Xi SY; Zhang Y; Huang QT; Wu QL; Wang F
Cell Death Dis; 2018 Oct; 9(11):1085. PubMed ID: 30348939
[TBL] [Abstract][Full Text] [Related]
7. TNF‑α‑mediated upregulation of SOD‑2 contributes to cell proliferation and cisplatin resistance in esophageal squamous cell carcinoma.
Zuo J; Zhao M; Liu B; Han X; Li Y; Wang W; Zhang Q; Lv P; Xing L; Shen H; Zhang X
Oncol Rep; 2019 Oct; 42(4):1497-1506. PubMed ID: 31364751
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of HOXA13 sensitizes human esophageal squamous cell carcinoma to chemotherapy.
Shi Q; Shen L; Dong B; Fu H; Kang X; Dai L; Yang Y; Yan W; Chen KN
Thorac Cancer; 2018 Jul; 9(7):836-846. PubMed ID: 29757528
[TBL] [Abstract][Full Text] [Related]
9. TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells.
Niwa N; Tanaka N; Hongo H; Miyazaki Y; Takamatsu K; Mizuno R; Kikuchi E; Mikami S; Kosaka T; Oya M
Lab Invest; 2019 Nov; 99(11):1702-1713. PubMed ID: 31263157
[TBL] [Abstract][Full Text] [Related]
10. MTA2 promotes the metastasis of esophageal squamous cell carcinoma via EIF4E-Twist feedback loop.
Dai SL; Wei SS; Zhang C; Li XY; Liu YP; Ma M; Lv HL; Zhang Z; Zhao LM; Shan BE
Cancer Sci; 2021 Mar; 112(3):1060-1074. PubMed ID: 33340431
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
12. THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5-fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis.
Hayashi M; Kawakubo H; Fukuda K; Mayanagi S; Nakamura R; Suda K; Hayashida T; Wada N; Kitagawa Y
J Gene Med; 2019 Dec; 21(12):e3135. PubMed ID: 31656051
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-mesenchymal transition and cancer stem cell-like phenotype induced by Twist1 contribute to acquired resistance to irinotecan in colon cancer.
Yang Y; Wang G; Zhu D; Huang Y; Luo Y; Su P; Chen X; Wang Q
Int J Oncol; 2017 Aug; 51(2):515-524. PubMed ID: 28627611
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway.
Zhao Y; Ma K; Yang S; Zhang X; Wang F; Zhang X; Liu H; Fan Q
Int J Oncol; 2018 Aug; 53(2):644-658. PubMed ID: 29767234
[TBL] [Abstract][Full Text] [Related]
15. Linkage between EMT and stemness state through molecular association between TWIST1 and NY-ESO1 in esophageal squamous cell carcinoma.
Ardalan Khales S; Abbaszadegan MR; Majd A; Forghanifard MM
Biochimie; 2019 Aug; 163():84-93. PubMed ID: 31158427
[TBL] [Abstract][Full Text] [Related]
16. Salinomycin reduces epithelial-mesenchymal transition-mediated multidrug resistance by modifying long noncoding RNA HOTTIP expression in gastric cancer cells.
Mao Z; Wu Y; Zhou J; Xing C
Anticancer Drugs; 2019 Oct; 30(9):892-899. PubMed ID: 30882398
[TBL] [Abstract][Full Text] [Related]
17. Establishment of Acquired Cisplatin Resistance in Ovarian Cancer Cell Lines Characterized by Enriched Metastatic Properties with Increased Twist Expression.
Bahar E; Kim JY; Kim HS; Yoon H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33076245
[TBL] [Abstract][Full Text] [Related]
18. linc‑ROR facilitates hepatocellular carcinoma resistance to doxorubicin by regulating TWIST1‑mediated epithelial‑mesenchymal transition.
Zhang Y; Wu W; Sun Q; Ye L; Zhou D; Wang W
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760121
[TBL] [Abstract][Full Text] [Related]
19. Par-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMT.
Tan J; You Y; Xu T; Yu P; Wu D; Deng H; Zhang Y; Bie P
Toxicol Lett; 2014 Jan; 224(1):7-15. PubMed ID: 24144893
[TBL] [Abstract][Full Text] [Related]
20. MAML1 promotes ESCC aggressiveness through upregulation of EMT marker TWIST1.
Forghanifard MM; Azaraz S; Ardalan Khales S; Morshedi Rad D; Abbaszadegan MR
Mol Biol Rep; 2020 Apr; 47(4):2659-2668. PubMed ID: 32180088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
